Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer

April 05, 2024 By The ASCO Post Staff

Judy C. Boughey, MD, of the Mayo Clinic, discusses findings from the I-SPY2 trial, which show that although the extent of residual disease and tumor biology in patients with breast cancer may impact outcomes, the type of axillary surgery after neoadjuvant chemotherapy does not (Abstract 3).

Related Content